Laura Newell, MD, Hematology, Portland, OR, OHSU Hospital

LauraFNewellMD

Hematology Portland, OR

Instructor, Medicine, Oregon Health and Science University School of Medicine

Dr. Newell is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Newell's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFELLOWSHIP
  • University of California Davis
    University of California DavisRESIDENCY
  • University of California Davis School of Medicine
    University of California Davis School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2011 - 2021
  • WA State Medical License
    WA State Medical License 2007 - 2012
  • CA State Medical License
    CA State Medical License 2005 - Present
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
    Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
    Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
    Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations